HCW Biologics Inc. develops fusion immunotherapeutics for diseases associated with chronic inflammation, including autoimmune disorders, proinflammatory diseases, cancer and senescence-associated dysplasia. Its recurring company updates center on the TOBI and TRBC discovery platforms and product candidates such as HCW9302, an IL-2 fusion immunotherapeutic, HCW11-018b, a T-cell engager for solid tumors, and HCW9206, a multi-cytokine fusion protein reagent used in CAR-T manufacturing research.
News about HCWB also covers clinical and preclinical program disclosures, research publications, licensing activity involving HCW11-006 and Trimmune, operating and financial results, capital-structure matters, shareholder voting topics and Nasdaq listing-status developments.
HCW Biologics Inc. (NASDAQ:HCWB) has announced the pricing of its initial public offering (IPO) of 7,000,000 shares at $8.00 per share, aiming for gross proceeds of approximately $56.0 million. The shares are set to trade on the Nasdaq Global Market starting July 20, 2021. The offering is anticipated to close around July 22, 2021, pending customary conditions. An additional 1,050,000 shares may be purchased by underwriters within 45 days. EF Hutton is the sole book-running manager for the offering.